Connect with us

BioPharma

ProText Mobility, Inc. (OTCMKTS: TXTM) RSA Medical Marijuana Dispensaries RSAMMD Reverse Merger Heating Up & Breaking Out

Published

on

ProText Mobility, Inc. (OTCMKTS: TXTM) is heating up again and breaking out northbound moving up 85% on Friday on $1.6 million in dollar volume. TXTM recently proved itself as one of the biggest runners in small caps moving up over 1000% after the Company announced the long awaited RSAMMD reverse merger when RSA Medical Marijuana Dispensaries RSAMMD™ The more we are learning about RSA Medical Marijuana Dispensaries RSAMMD™ the more interesting it becomes. RSAMMD in Joint Venture with Leeds Boerdery, cultivated hemp and cannabis crops this past season on a combined 1000+ hectares. According to RSAMMD website they produced 35,000 kilograms on 1,000 hectares plot sitting on a 5,000-hectare farm so there is lots of room for expansion. They could also greatly increase their yield per hectare as compared to many Companies that can easily get 1,000 kilos per hectare. Currently trading at a $31 million market valuation TXTM has a lot of room to grow. 

RSAMMD run by CEO Dylon Du Plooy has a lot going on behind the scenes and thanks to Dylon Du Plooy we are able to get a glimpse. Mr. Plooy recently stated on twitter: “We Are Establishing The $TXTM Tribal Council Website is Looking Awesome, We Had a Last Minute Thought  #TXTMTribe Registration: Contact Details, LOCATION, HUMAN Capital You Adding, SHARES You Own, Price Bought in and Your Pledge to Humanity. Last week Mr. Plooy stated: “So When Roger Spoke of $45 Million Dollars Per Day that Was Years Ago Before Inflation Before Multiple Applications of The Technology For Natural Plant Based Treatments Before #DrJ Came in As The Chairman Of The Commodity Board for Cannabis & All Indigenous Flora We Got Roger to Gather Some Strength to Get Down to Leeds to Run The Test. We Saw First Hand the Technology Was Working before #DrJ Came in As The Chairman Of The Commodity Board for Cannabis & All Indigenous Flora. TXTM has recent highs of $0.0191, a break over and its blue skies ahead. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

RSA Medical Marijuana Dispensaries RSAMMD™ is a fully licensed health practitioners, qualified to dispense and prescribe medical cannabis in South Africa. The Company offers superior patient care and 100% Indoor and greenhouse grown cannabis ensuring patients receive clean, safe, and pure medical cannabis products. RSAMMD has 2 commerical licenses, 1 dispensing, importation & prescription license, 2 permits, 1 seed bank cultivar and with an annual production of 35,000 kilograms per year.

On June 13 (reverse merger) Republic of South Africa Medical Marijuana Dispensaries Acquisitions LLC (“RSAMMDA.LLC”) announced it has closed on the acquisition of Protext Mobility, Inc (OTC PINK: TXTM) (A.K.A. Protext Pharma) in a share exchange whereby 100% of capital stock in RSAMMDA.LLC will be exchanged for Preferred Stock in Protext. RSAMMDA.LLC. is a jointly owned company focused on acquistions with two principals, Mr. Dylon Du Plooy and Dr. Ahmed Jamaloodeen (“Dr. J”) who represent the South African business entities of RSAMMD and Leeds Boerdery. RSAMMD is a South African pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids. Leeds Boerdery, controlled by Dr. J, owns the 5000 Hectacre New Castle Farm as well as federally issued cannabis and hemp licenses issued by the Government of South Africa. RSAMMD management have taken over the daily operations of Protext headed by Mr. Du Plooy as CEO and Director, and Dr. Jamaloodeen as President and Chairman of the Board. 

To Find out the inside Scoop on TXTM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

TXTM

Mr. Dylon Du Plooy, Protext CEO and Principal of RSAMMD.LLC, commented at the time, “This transaction has been a long time in the making. For the past couple years we have been focused on building our operations in South Africa and globally, where have built an extensive infrastructure and global cannabis/hemp business. During this period of time, we have invested heavily in building a significant cannabis/hemp operation to facilitate complete seed to sale, R&D, global off-take agreements for end product as well as all the extraction infrastructure needed to create what we believe to be some of the highest quality hemp and cannabis on the planet. In South Africa right now, we have just completed our semi-annual grow. RSAMMD in Joint Venture with Leeds Boerdery, cultivated hemp and cannabis crops this past season on a combined 1000+ hectacres. All of this is done under federally issued permits and licenses to grow, import/export hemp and cannabis, as well as research permits for conducting testing of final products for human consumption and medicinal benefits. Over the coming days and weeks, we will be sharing our immediate term road map and long-term plans we are developing for Protext which should translate into increasing shareholder value. These plans include adding other valuable assets to the company which complement the core business, and executing on commercializing the proprietary live plant extraction technology as well as deploying our crypto platform, with a TXTM token which we are excited to rollout very soon.” 

Fore More on TXTM Subscribe Right Now!

Currently trading at a $60 million market valuation TXTM is the perfect RM runner with a far better share structure than HMBL/TSNP did by far and it’s got power TXTM traded $1.6 million in dollar volume on Friday alone. The more we are learning about RSA Medical Marijuana Dispensaries RSAMMD™ the more interesting and exciting it becomes. RSAMMD in Joint Venture with Leeds Boerdery, cultivated hemp and cannabis crops this past season on a combined 1000+ hectares. According to RSAMMD website they produced 35,000 kilograms on 1,000 hectares plot sitting on a 5,000-hectare farm so there is lots of room for expansion. 35,000kg at USD $2,450 per kilo based on $1,114 bulk price per pound of cannabis RSAMMD current annual production is worth $85,750,000. The Company could see a 5-fold increase in production on the farm they are currently on. They could also greatly increase their yield per hectare as compared to many Companies that can easily get 1,000 kilos per hectare. RSAMMD CEO Mr. Du Plooy said that the Company will be updating shareholders in the coming days and sharing its immediate term road map and long-term plans it is developing for Protext which should translate into increasing shareholder value. These plans include adding other valuable assets to the company which complement the core business, and executing on commercializing the proprietary live plant extraction technology as well as deploying the crypto platform, with a TXTM token. Microcapdaily will be covering RSAMMD as it happens so make sure you subscribe to Microcapdaily right now so you don’t miss it. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in TXTM either long or short and we have not been compensated for this article.

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

BioPharma

Vaccitech (NASDAQ: VACC) Gains Unprecedented Support—What’s Behind It?

Published

on

On September 25, 2023, Vaccitech (NASDAQ: VACC) experienced a jaw-dropping 90% surge in its stock price in just one day of trading. Now, this kind of jump usually happens when a company drops a major announcement or puts out a significant SEC filing. But, surprise, surprise—there was nothing of that sort this time .So naturally we did some digging, explored further online and guess what? Turns out retail traders were also not on a main reason for this rollercoaster ride. Curious to uncover what’s really behind this financial rollercoaster? Before we go any further, let’s get to know Vaccitech a bit better. There’s some pretty important aspects on the company you might like.

 

Background:

Vaccitech operates as a clinical-stage biopharmaceutical company, dedicated to discovering and developing innovative T cell immunotherapies. These therapies are crafted to leverage the immune system’s potency for treating conditions like chronic infectious diseases, cancer, and autoimmune disorders.

What sets Vaccitech apart is their distinctive, multi-platform approach, demonstrating the capacity to generate higher quantities of T cells compared to alternative technologies. This places Vaccitech in a unique position to cater to the needs of substantial, yet underserved patient populations. Their diverse clinical-stage pipeline includes potential treatments for severe diseases with limited available treatments, presenting significant public health risks.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Among their lead product candidates are VTP-300, an immunotherapeutic designed to contribute to a potential functional cure for chronic hepatitis B viral (HBV) infection. Additionally, VTP-200 is a non-invasive, early-stage investigational treatment targeting persistent, high-risk human papillomavirus (HPV). VTP-850 stands out as a novel T cell investigational therapy aimed at prostate cancer, while VTP-1000, a preclinical T cell therapeutic candidate, focuses on reinstating immune tolerance in celiac disease.

Vaccitech possesses well-established expertise in drug development and scientific knowledge within the immunization realm. Notably, they co-developed a COVID-19 vaccine in collaboration with the University of Oxford. As many of you know, their vaccine has been successfully approved and holds an exclusive license worldwide with AstraZeneca.

What happened:

The one and only thing that happened today was Alliance Global Partners adding coverage of Vaccitech with a favourable buy recommendation.What’s truly eye-catching are the projections made, suggesting some pretty significant upside. The average one-year price target for Vaccitech is $12.24. Forecasts within this period have a bit of a spectrum, reaching from a low estimate of $7.07 to a high of $15.75. With that said, from today’s closing price that’s nearly 400% gain.

What’s The Big Deal?:

Alliance Global Partners giving the green light to cover Vaccitech is like a thumbs-up from a respected expert. It’s like a top-tier food critic saying, “This restaurant is a must-try.”

Think of it as Vaccitech stepping into the spotlight. It’s like a talented musician getting featured on a famous music blog—suddenly, more people start paying attention.

When a big player like Alliance Global Partners says, “Hey, this stock is a good buy,” it’s like a friend recommending a must-watch movie. You’re more likely to check it out based on that suggestion.

This kind of recommendation can also affect the stock price. It’s similar to when a popular influencer talks about a cool product—lots of people want to try it.

In a nutshell, this coverage is like a stamp of approval, making Vaccitech catch the attention of more potential investors and possibly giving the stock a boost. But it’s important to mention that just because a well established financial firm gives a price target, does not mean it’s accurate. In fact, tons of these projections are made daily with many being totally off the mark. Always do your own due diligence.

We will update you on VACC when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by spencerbdavis1 from Pixabay

 

 

 

Continue Reading

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.